A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors

Clinical trial NCT02223247 · COMPLETED

Trial details

NCT number: NCT02223247
Sponsor: Sagimet Biosciences Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Malignant Tumor

Start date: 2013-11-01
Primary completion: 2017-06-01
Enrollment: 180

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.